Q1 2025 Earnings Summary
Metric | YoY Change | Reason |
---|---|---|
Total Revenue | +6.7% (from $566.655M to $604.702M) | The increase is attributed to sustained market demand and improved pricing strategies, driving revenue growth from $566.655M in Q1 2024 to $604.702M in Q1 2025. |
Operating Income | Reversed from a loss of $10.655M to a profit of $12.888M | The turnaround in operating income is driven by better operating efficiencies, cost control, and an improved product mix that helped transform a loss into profitability. |
Gross Profit | +13.4% (from $185.244M to $210.109M) | The gross profit improvement reflects enhanced production margins and effective cost management measures, increasing from $185.244M in Q1 2024 to $210.109M in Q1 2025. |
Net Loss | Reduced by 60% (from $39.471M to $15.476M) | The significant narrowing of the net loss is driven by operational leverage gains and margin improvements, decreasing the loss from $39.471M to $15.476M, indicating focused cost and efficiency measures. |
Metric | Period | Guidance | Actual | Performance |
---|---|---|---|---|
Revenue YoY | Q1 2025 | Low- to mid-single-digit growth range | 6.7% YoY growth (from 566.655MTo 604.702M) | Beat |
Research analysts covering ICU MEDICAL INC/DE.